We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

12 hedge funds and large institutions have $2.41M invested in Panbela Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 → 12 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

23% less capital invested

Capital invested by funds: $3.12M → $2.41M (-$711K)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$58.5K
2
Goldman Sachs
Goldman Sachs
New York
+$58.5K
3
Millennium Management
Millennium Management
New York
+$58.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$58.5K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$118K
2
NAM
NewGen Asset Management
Ontario, Canada
-$113K
3
BFM
Boothbay Fund Management
New York
-$58.5K
4
WAM
Warberg Asset Management
Illinois
-$33K
5
PC
Permanens Capital
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$734K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$495K +$58.5K +1 +11%
M
3
Murchinson
Ontario, Canada
$326K – – –
FPS
4
Fieldpoint Private Securities
Connecticut
$301K – – –
BAMG
5
Brand Asset Management Group
Missouri
$124K – – –
BFM
6
Boothbay Fund Management
New York
$74K -$58.5K -1 -50%
Millennium Management
7
Millennium Management
New York
$72K +$58.5K +1 New
BlackRock
8
BlackRock
New York
$64K – – –
BSW
9
Buckingham Strategic Wealth
Missouri
$54K – – –
Goldman Sachs
10
Goldman Sachs
New York
$52K +$58.5K +1 New
Verition Fund Management
11
Verition Fund Management
Connecticut
$43K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$43K +$58.5K +1 New
Morgan Stanley
13
Morgan Stanley
New York
$15K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$7K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$5K – – –
UBS Group
16
UBS Group
Switzerland
$2K – – –
Northwestern Mutual Wealth Management
17
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
CH
18
CVI Holdings
Delaware
– -$118K -2 Closed
NAM
19
NewGen Asset Management
Ontario, Canada
– -$113K -2 Closed
PC
20
Permanens Capital
New York
– -$1K – –
WAM
21
Warberg Asset Management
Illinois
– -$33K – –

PBLA Hedge Fund Activity: Q3 2021 in Review

12 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q3 2021, worth a combined $2.41M — down 23% from $3.12M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PBLA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $58.5K. The largest seller was CVI Holdings, exiting entirely with an estimated $118K sold.

  • 12 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q3 2021, up from 11 in Q2 2021.
  • Funds reported $2.41M of Panbela Therapeutics, Inc. Common Stock stock for Q3 2021, down 23% quarter-over-quarter.
  • 3 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q3 2021 and 2 closed out, a net change of +1 holder.
  • The largest Panbela Therapeutics, Inc. Common Stock buyer in Q3 2021 was Citadel Advisors, an estimated $58.5K added.
  • The largest Panbela Therapeutics, Inc. Common Stock seller in Q3 2021 was CVI Holdings, an estimated $118K sold.

Based on aggregated 13F filings for Q3 2021.